Navigation Links
Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
Date:9/11/2009

MONMOUTH JUNCTION, N.J., Sept. 11 /PRNewswire/ -- Signum Biosciences, Inc has been awarded a $1.6 million Small Business Innovation Research (SBIR) Phase II grant by the National Institute of Allergy and Infection Diseases (NIAID) to continue the development of its topical STM (Signal Transduction Modulator) anti-inflammatory technology for the treatment of inflammatory skin disease.

In 2008, NIH/NIAID awarded Signum a SBIR Phase I grant to establish this novel class of anti-inflammatories. SBIR Phase II grants enable SBIR Phase I grantees to further develop their technology and prepare it for commercialization. Signum will use the Phase II grant to fund preclinical development of Signum's lead drug candidates for rosacea. Rosacea is a common, chronic cutaneous condition afflicting millions of individuals. FDA approved treatments have yielded mixed results, often leaving patients with significant levels of facial redness. Successful pharmaceutical development of STM anti-inflammatories will provide an important additional, and potentially better, therapeutic option for people suffering from rosacea redness.

The objective of the Phase II grant is to be granted an IND and commence Phase I clinical trials. "We are proud to have been awarded this grant and to have the reviewers at the NIH validate our technology. Building on our Phase I achievements, Signum is dedicated to developing its STM anti-inflammatory platform as novel therapeutics for rosacea as well as several other dermal skin disorders", stated Maxwell Stock, President and Chief Operating Officer.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation platform. Signum is a pioneer of this new technology which modulates targets rather than just switching-them on or off. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, and several skin conditions. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates. For more information please visit the Signum website: www.signumbiosciences.com.


'/>"/>
SOURCE Signum Biosciences, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
2. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
3. Neurocrine Biosciences Presents Elagolix Data
4. SAFC Biosciences(R) and Vivalis Collaborate to Optimize Cell Culture Media for Vaccines Production
5. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
6. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
7. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
8. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
9. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
10. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
11. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2017)... May 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... big data solutions, today announced that it is teaming ... STI Technologies Limited to lower diabetes healthcare costs in ... innoviCares card, which is available throughout all provinces and ... will be eligible for additional savings when shopping for ...
(Date:5/3/2017)... 2017 A Catheterization Laboratory is an ... facility. Commonly referred to as cath lab, this ... imaging technology to give physicians visual access to ... spaces, a team of physicians perform life-saving procedures ... intervention, congenital heart defect closure, stenotic heart valves, ...
(Date:5/3/2017)... Pa. , May 3, 2017  West ... in innovative solutions for injectable drug administration, announced ... Scientific Affairs and Technical Services, and Diane ... workshops and offering presentations focused on West,s expertise ... injectable products, as well as providing commentary on ...
Breaking Medicine Technology:
(Date:5/26/2017)... MN (PRWEB) , ... May 26, 2017 , ... A ... U.S. states with the healthiest seniors are located in the Midwest. With the average ... more and more people are concerned with both the quality and affordability of where ...
(Date:5/26/2017)... , ... May 26, 2017 , ... After raising nearly ... Top gadget will continue to be available at a discounted crowdfunding price on ... stress wherever they are, I also wanted to bring a fidget toy to the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Dr. Alex Rabinovich, a highly-skilled oral surgeon specializing ... blog post on insurance options. If a Bay Area patient has to search for ... and money. Visiting an in-network provider for a second opinion can ensure a patient ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: ... the Garden of Eden” is the creation of published author, Penelope Colt, mother, trader, horse ... family moved to NYC when she was three. At six, they moved to Dayton, ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success ... appropriate instruments for research and understanding the basic principles that were designed to ... on innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories ...
Breaking Medicine News(10 mins):